Wang; Rong-Fu

Patent Applications and Registrations

Patent applications and USPTO patent grants for Wang; Rong-Fu.The latest application filed is for "novel mhc class ii restricted t cell epitopes from the cancer antigen, ny eso-1".

Company Profile

1.11.9

Wang; Rong-Fu - Houston TX
Wang; Rong Fu - Bethesda MD

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 Grant 10,251,912 - Wang , et al.	2019-04-09
Novel Mhc Class Ii Restricted T Cell Epitopes From The Cancer Antigen, Ny Eso-1 App 20160354409 - Wang; Rong-Fu ; et al.	2016-12-08
MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 Grant 9,447,144 - Wang , et al. September 20, 2	2016-09-20
Novel Mhc Class Ii Restricted T Cell Epitopes From The Cancer Antigen, Ny Eso-1 App 20140335053 - Wang; Rong-Fu ; et al.	2014-11-13
MHC class II restricted T cell epitopes from the cancer anitgen, NY ESO-1 Grant 8,754,046 - Wang , et al. June 17, 2	2014-06-17
Nlrc5 As A Target For Immune Therapy App 20110229560 - Wang; Rong-Fu ; et al.	2011-09-22
Novel Mhc Class Ii Restricted T Cell Epitopes From The Cancer Anitgen, Ny Eso-1 App 20100021468 - Wang; Rong-Fu ; et al.	2010-01-28
MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 Grant 7,619,057 - Wang , et al. November 17, 2	2009-11-17
Direct Reversal Of The Suppressive Function Of CD4+Regulatory T Cells Via Toll-Like Receptor 8 Signaling App 20090209620 - Wang; Rong-Fu ; et al.	2009-08-20
Reversal Of The Suppressive Function Of Specific T Cells Via Toll-like Receptor 8 Signaling App 20080026986 - Wang; Rong-Fu ; et al.	2008-01-31
Cancer peptides of NY-ESO-1/CAG-3 Grant 7,084,239 - Wang , et al. August 1, 2	2006-08-01
Antibodies to the protein product encoded by ORF3 of the TRP-1 gene and compositions and kits thereof Grant 7,015,312 - Wang , et al. March 21, 2	2006-03-21
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes Grant 7,001,600 - Wang , et al. February 21, 2	2006-02-21
Novel mhc class II restricted t cell epitopes from the cancer antigen, ny eso-1 App 20050136402 - Wang, Rong-Fu ; et al.	2005-06-23
Mutant fibronectin and tumor metastasis App 20040023314 - Wang, Rong-Fu	2004-02-05
Use of cell-penetrating peptides to generate antitumor immunity App 20030077289 - Wang, Rong-Fu	2003-04-24
Antibodies specific for TRP-2 a human tumor antigen recognized by cytotoxic T lymphocytes Grant 6,132,980 - Wang , et al. October 17, 2	2000-10-17
Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein Grant 5,840,839 - Wang , et al. November 24, 1	1998-11-24
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes Grant 5,831,016 - Wang , et al. November 3, 1	1998-11-03

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.